awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q49177202-54C6D81F-E1F2-4762-9C11-F26469E0EAB6
Q49177202-54C6D81F-E1F2-4762-9C11-F26469E0EAB6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49177202-54C6D81F-E1F2-4762-9C11-F26469E0EAB6
A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.
P2860
Q49177202-54C6D81F-E1F2-4762-9C11-F26469E0EAB6
BestRank
Statement
http://www.wikidata.org/entity/statement/Q49177202-54C6D81F-E1F2-4762-9C11-F26469E0EAB6
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
70d1d04c99df3f13f44db34e14ce71c1ad76f235
P2860
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l